Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Cannabis: Medical Treatments

Department of Health and Social Care written question – answered on 30th January 2020.

Alert me about debates like this

Photo of Mark Garnier Mark Garnier Conservative, Wyre Forest

To ask the Secretary of State for Health and Social Care, what the average cost to the NHS was of prescriptions for unlicensed cannabis-based products for medicinal use from November 2018 to October 2019.

Photo of Mark Garnier Mark Garnier Conservative, Wyre Forest

To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone Savitex, (b) Epidiolex and (c) unlicensed cannabis-based products for medicinal use were dispensed by hospital pharmacies from November 2018 to October 2019.

Photo of Mark Garnier Mark Garnier Conservative, Wyre Forest

To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone, (b) Savitex and (c) unlicensed cannabis-based products for medicinal use were issued by private healthcare specialist prescribers and dispensed in the community in October 2019.

Photo of Mark Garnier Mark Garnier Conservative, Wyre Forest

To ask the Secretary of State for Health and Social Care, how many prescriptions for unlicensed cannabis-based products for medicinal use were prescribed by the NHS and dispensed in the community in October 2019.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Does this answer the above question?

Yes2 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.